Lupin, one of the leading pharmaceutical companies in India, today announced a sharp growth of 55.17% in its consolidated net profit for the quarter ended Sept. 30, 2014. Analysts, on average, expected Lupin to report a profit of Rs 5.50 billion, on revenue of Rs 32.7 billion.
 
Net profit for the quarter stood at Rs 6.30 billion against Rs 4.06 billion for the same period in the previous year.

During the quarter, total income increased 19% to Rs 31.73 billion from Rs 26.68 billion in the year ago period.

EBITDA grew by 27.2% to Rs 9,428 million during Q2 FY 2014-15, up from Rs 7,410 million in Q2 FY 2013-14.

Nilesh Gupta, managing director, Lupin, said, ''We have had a great first half driven by strong growth in US, India, Japan and our API business. Our research pipeline is evolving well and we expect significant developments in the dermatology and inhalation space in the quarters to come.''

Shares of the company declined Rs 11.05, or 0.79%, to trade at Rs 1,383. The total volume of shares traded was 241,128 at the BSE (1.43 p.m., Tuesday).